Sustained effect of health insurance and facility quality improvement on blood pressure in adults with hypertension in Nigeria: A population-based study  by Hendriks, Marleen E. et al.
International Journal of Cardiology 202 (2016) 477–484
Contents lists available at ScienceDirect
International Journal of Cardiology
j ourna l homepage: www.e lsev ie r .com/ locate / i j ca rdSustained effect of health insurance and facility quality improvement
on blood pressure in adults with hypertension in Nigeria:
A population-based studyMarleen E. Hendriks a,⁎,1,2, Nicole T.A. Rosendaal a,1,2, Ferdinand W.N.M. Wit a,2, Oladimeji A. Bolarinwa b,2,
Berber Kramer c,d,2, Daniëlla Brals a,2, Emily Gustafsson-Wright d,e,2, Peju Adenusi f,2, Lizzy M. Brewster g,2,
Gordon K. Osagbemi b,2, Tanimola M. Akande b,2, Constance Schultsz a,2
a Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam Institute for Global Health and Development, Pietersbergweg 17, Amsterdam, 1105 BM, the
Netherlands
b Department of Epidemiology and Community Health, University of Ilorin Teaching Hospital, P.M.B. 1459, Ilorin 240001, Nigeria
c International Food Policy Research Institute, Markets, Trade and Institutions Division, 2033 K St, NW, Washington, DC 20006-1002, United States
d Amsterdam Institute for International Development, Pietersbergweg 17, Amsterdam, 1105 BM, the Netherlands
e Brookings Institution, 1775 Massachusetts Ave, NW, Washington, DC 20036, Unites States
f Hygeia Nigeria Ltd, 13B Idejo Street, Victoria Island, Lagos, Nigeria
g Departments of Internal and Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam Institute for Global Health and Development, Meibergdreef 9, 1105 AZ,
Amsterdam, the Netherlands⁎ Corresponding author.
E-mail address:m.hendriks@aighd.org (M.E. Hendriks
1 These authors contributed equally to this manuscript
2 This author takes responsibility for all aspects of the r
of the data presented and their discussed interpretation.
http://dx.doi.org/10.1016/j.ijcard.2015.09.036
0167-5273/© 2015 The Authors. Published by Elsevier Irea b s t r a c ta r t i c l e i n f oArticle history:
Received 30 July 2015
Received in revised form 9 September 2015
Accepted 19 September 2015
Available online 21 September 2015
Keywords:
Health insurance
Quality of care
Access to care
Hypertension
Nigeria
Sub-Saharan AfricaBackground: Hypertension is a leading risk factor for death in sub-Saharan Africa. Quality treatment is often not
available nor affordable. We assessed the effect of a voluntary health insurance program, including quality im-
provement of healthcare facilities, on blood pressure (BP) in hypertensive adults in rural Nigeria.
Methods: We compared changes in outcomes from baseline (2009) to midline (2011) and endline (2013) be-
tween non-pregnant hypertensive adults in the insurance program area (PA) and a control area (CA), through
household surveys. The primary outcome was the difference between the PA and CA in change in BP, using
difference-in-differences analysis.
Results: Of 1500 eligible households, 1450 (96.7%) participated, including 559 (20.8%) hypertensive individuals,
of which 332 (59.4%) had follow-up data. Insurance coverage increased from0% at baseline to 41.8% at endline in
the PA and remained under 1% in the CA. The PA showed a 4.97mmHg (95% CI:−0.76 to+10.71mmHg) great-
er decrease in systolic BP and a 1.81mmHg (−1.06 to+4.68mmHg) greater decrease in diastolic BP frombase-
line to endline compared to the CA. Respondents with stage 2 hypertension showed an 11.43 mm Hg (95% CI:
1.62 to 21.23mmHg) greater reduction in systolic BP and 3.15mmHg (−1.22 to+7.53mmHg) greater reduc-
tion in diastolic BP in the PA compared to the CA. Attrition did not affect the results.
Conclusion: Access to improved quality healthcare through an insurance program in rural Nigeria was associated
with a signiﬁcant longer-term reduction in systolic BP in subjects with moderate or severe hypertension.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hypertension is one of the main risk factors for premature death in
adults in sub-Saharan Africa (SSA) due to associated cardiovascular
disease (CVD) [1]. The age-standardized prevalence of hypertension in
SSA increased from 19.1% in 1990 to 25.9% in 2010 [2]. Reduction of
blood pressure (BP) greatly reduces the risk of CVD [3]. However,).
.
eliability and freedom from bias
land Ltd. This is an open access articlantihypertensive treatment coverage in SSA is low due to low aware-
ness of hypertension, and poor availability of quality care for hyperten-
sion [4,5]. In addition, hypertension treatment is often not affordable for
patients. In Nigeria, almost 66% of healthcare expenditures are paid out-
of-pocket by patients [6]. We investigated whether a health insurance
program targeted at low-income groups, which included quality im-
provement of health facilities, could be used to provide effective care
for hypertension in rural Nigeria. We previously demonstrated that
the Kwara State Health Insurance (KSHI) program (formerly known as
the Hygeia Community Health Care program) resulted in a signiﬁcant
reduction in BP in subjects with hypertension (21% of the target popula-
tion [5]), two years after the introduction of the program [7]. However,e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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longer-term effect of the KSHI program on BP in the hypertensive
population and, in addition to our previous study, we evaluated the
contribution of improved quality of care in the program clinics.
2. Methods
The KSHI program is a voluntary health insurance program that aims to improve
access to affordable quality healthcare for people in rural communities of Kwara State,
Nigeria. The program provides coverage for primary and limited secondary healthcare,
including antihypertensive treatment. In addition, the program improves the quality of
care in healthcare facilities participating in the program by upgrading of facilities, training
of staff in guideline-based care, and hospital management support (see supplemental
material [eMethods] for a more detailed description of the program) [7].
2.1. Study design and population
Weused a quasi-experimental design tomeasure the effect of theKSHI programonBP
in hypertensive adults. We compared changes in outcomes from baseline (pre-program)
with those found at midline after 2 years of follow up (short-term) and at endline after
4 years of follow-up (longer-term), in a program area (PA) and in a control area (CA)
where the program was not implemented. The difference in changes from baseline
between the PA and CA represents the true program effect.
The study population of non-pregnant adults with hypertension was derived from a
population-based sample of the Afon and Ajasse Ipo districts in Kwara State. Both districts
were low-income rural communities with comparable availability and quality of
healthcare services at baseline (see supplemental material [eMethods] for more details
on the population and setting) [7]. The KSHI program has been offered to households in
the Afon district (the PA) since 2009. The program was not operational in the CA, Ajasse
Ipo. Consecutive population-based household surveyswere conducted tomeasure chang-
es in outcomes over time. Householdmemberswere interviewed and BPwasmeasured in
both areas during the baseline survey in May and June 2009, before the roll out of the in-
surance program [7]. Households were revisited during the same months for the midline
(2011) and endline (2013) surveys. All non-pregnant adults (aged ≥18 years) among
3023 community-dwelling adults who were hypertensive at baseline were eligible for
this study. Only eligible individuals with complete follow-up data were included in the
analysis.
2.2. Sampling and sample size
A stratiﬁed probability sample was drawn from a random sample of enumeration
areas and a random sampleof households in 2009. The target sample sizewas 1500house-
holds whichwas deﬁned based on outcomes to measure the socioeconomic impact of the
program [7]. More information about the sampling procedures is given in the supplemen-
tal material (eMethods).
2.3. Data collection
Questionnaires to collect demographic, socioeconomic, andmedical informationwere
administered by trained interviewers. BP was measured 3 times on the upper left arm in
upright position after at least 5 minutes of rest using a validated automated BP device
(Omron M6 Comfort; Omron Corporation). The mean value of the second and third
measurement was used for analyses [7]. In both areas, respondents with systolic blood
pressure (SBP) ≥140 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg were advised
to see a healthcare professional andwere providedwith an information leaﬂet. Amedicine
cabinet survey was conducted in 2013, in which all medications present in the household
were identiﬁed, each medication was linked to individual household members, and the
source (formal or informal provider) was registered [8].
2.4. Ethical review
Ethical clearancewas obtained from the ethical review committee of the University of
Ilorin Teaching Hospital (04/08/2008, UITH/CAT/189/11/782). Informed consent was
obtained from all participants by signature or by ﬁngerprint [7].
2.5. Data analysis
Hypertension was deﬁned as measured SBP ≥140 mm Hg, and/or DBP ≥90 mm Hg,
and/or (self-reported) drug treatment for hypertension [7]. Hypertension stages 1 and 2
were deﬁned as SBP between 140–159 and ≥160mmHg respectively and/or DBP between
90–99 and ≥100 mm Hg respectively [9]. Treatment of hypertension was deﬁned as
individual-linked hypertension medication observed in the medicine cabinet survey, or
self-reported hypertension medication use. Control of BP (controlled hypertension) was
deﬁned as measured SBP b140 mm Hg and DBP b90 mm Hg [7]. Use of healthcare for
hypertension was deﬁned as a visit to a formal healthcare provider for hypertension in
the last 12 months. A formal healthcare provider included public and private hospitals
and clinics, primary healthcare centers, private physicians and nurses, and pharmacists.
Informal providers included patent medicine vendors and traditional medicine practi-
tioners and vendors [7].The difference between the PA and CA in the change inmean SBP and DBP from base-
line tomidline and baseline to endlinewas predeﬁned as the primary outcome tomeasure
the effect of the program on health status in the population with hypertension at baseline
[7]. Additionally, a pre-deﬁned subgroup analysis based on hypertension severity at base-
line was performed. The differences in control of BP and in antihypertensive drug treat-
ment coverage between respondents in the PA and CA over time constituted secondary
outcome measures. In addition to these outcome measures, we used proxies for quality
of care to evaluate differences in quality between the two areas, in the endline survey.
These included the intensity of healthcare utilization for hypertension, source of hyperten-
sionmedication (formal healthcare provider versus an informal provider) and association
with BP reduction, and adherence to antihypertensive medication.
2.6. Statistical analysis
We analyzed the data using Stata (version 12.0; StataCorp). We analyzed population
characteristics of the participants with hypertension in the PA and CA using descriptive
statistics. We compared groups using bivariable analysis (Kruskal–Wallis test for continu-
ous variables, Pearson χ2 test or Fisher exact test for categorical variables, and non-
parametric trend test for ordinal scales) [7]. Difference-in-differences analyses with
ﬁxed effects [10]were performed to compare changes in outcome over time.With this ap-
proach, all respondents in the PAwere considered to be in the intervention group irrespec-
tive of whether respondents were actually insured. Such an intention-to-treat approach
eliminates the bias introduced by self-selection into (or out of) the insurance program
and incorporates potential spillover effects on uninsured respondents who might also
beneﬁt from the quality improvement of the healthcare facilities in the PA [7]. Biomedical
and socioeconomic confounders were deﬁned a priori and included in the models irre-
spective of statistical signiﬁcance. The variables included were body mass index, diabetes
mellitus, smoking status, assets, the value of household food consumption and expendi-
tures on nonfood items (a socioeconomic measure that proxies a household's yearly
income, hereinafter referred to as consumption), employment, household size, being
the head of the household, and marital status. The common trend assumption in a
difference-in-differences analysis is that the two groups compared show the same trend
over time without the intervention [10]. Baseline differences between the groups being
comparedmay inﬂuence the effect of the intervention or the effect of the baseline screen-
ing of BP and possibly undermine the common trend assumption. Therefore, we corrected
for baseline differences by including an interaction between time (follow-up survey year)
and a priori selected characteristics, if signiﬁcant at a 0.10 signiﬁcance level [11]. These in-
cluded interactions between follow-up survey year and age, gender, baseline BP (primary
outcomes) or baseline hypertension severity (secondary outcomes), educational level,
religious afﬁliation and consumption. Furthermore, we performed a multivariable linear
regression analysis to evaluate the association between the location where respondents
obtained antihypertensive medication (source of medication) and BP reduction from
baseline to endline. Confounders were selected a-priori and included in the model when
statistically relevant (P b 0.10). All estimates were corrected for clustering at enumeration
area level and lower levels of clustering such as household and individual level. To evalu-
ate the effect of missing data (mainly because of attrition), sensitivity analyses using
inverse probability weighting were performed for the main outcome measures.
3. Results
3.1. Survey response rate and attrition
Of the 1500 sampled households, 187 households could not be
located and were replaced by other households to reach the sample
size of 1500, at baseline. Of 1500 eligible households, 1450 (96.7%) par-
ticipated in the survey, including 559 non-pregnant adults identiﬁed
with hypertension at baseline (309 of 1637 non-pregnant adults in
the PA [18.9%] and 250 of 1048 in the CA [23.9%]). Longitudinal data
were available for 332 hypertensive adults (59.4%); 194 (62.8%) in the
PA and 138 (55.2%) in the CA (Fig. 1).
Thirty-one respondents (10%) died between 2009 and 2013 in the
PA compared to 19 respondents (7.6%) in the CA (P=0.32). Frequently
reported causes of death were infectious diseases and old age. In both
the PA and CA, stroke was the cause of death for two subjects, and
diabetes complications for one subject.
3.2. Population characteristics at baseline
Median agewas 60 (IQR, 48–70) in the PA compared to 55 (IQR, 47–
62) (P=0.05) in the CA. The percentage of females was 71.6% in the PA
compared to 59.4% (P = 0.02) in the CA. Median BMI was 22.7 (IQR,
20.3–26.2) in the PA compared to 24.2 (IQR, 21.1–27.8) (P = 0.02) in
the CA. Median consumption was USD 655.8 (IQR, 426–1079) in the
PA compared to USD 819.6 (IQR, 583–1190) (P = 0.001) in the CA. In
Fig. 1. Participation in the 2009, 2011 and 2013 surveys and reasons for attrition.
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education compared to 48.6% in the CA (P= 0.001). In the PA 29.4% of
the respondents had visited a formal healthcare provider in the 12
months prior to the baseline survey compared to 39.9% of respondents
in the CA (P = 0.05). Mean BP and median healthcare expenditure
were similar in the two areas at baseline (Table 1).3.3. Insurance enrollment
None of the hypertensive respondents in the PA and one respondent
in the CA (0.5%) were insured at baseline (Table 1). Both at midline and
endline, 41.8% of the respondents were insured in the PA. None of the
respondents in the CAwere insured at themidline and endline surveys.
Table 1
Characteristics of respondents with hypertension at baseline in 2009, 2011 and 2013.
Characteristic 2009 2011 2013
Control area
(N= 138)
Program area
(N= 194)
P-valuea Control area
(N= 138)
Program area
(N= 194)
P-valuea Control area
(N= 138)
Program area
(N= 194)
P-valuea
Male sex, n (%) 56 (40.6) 55 (28.4) 0.02 56 (40.6) 55 (28.4) 0.02 56 (40.6) 55 (28.4) 0.02
Age, median (IQR) 55 (47–62) 60 (48–70) 0.05 57 (49–64) 62 (50–72) 0.05 59 (51–66) 64 (52–74) 0.05
BMI, median (IQR) 24.2 (21.1–27.8) 22.7 (20.3–26.3 0.02 24.2 (21.1–28.1) 22.5 (20.2–26.8) 0.03 24.2 (20.8–28.7) 23.1 (20.3–27.1) 0.07
SBP, mean (SD) 156.4 (23.3) 154.6 (18.9) 0.60 150.7 (24.4) 145.3 (24.7) 0.06 154.2 (30.8) 149.5 (24.9) 0.34
DBP, mean (SD) 98.0 (12.5) 96.0 (10.4) 0.33 95.0 (13.4) 91.3 (13.7) 0.005 94.9 (16.3) 92.1 (13.7) 0.24
Aware of HT, n (%) 11 (8.0) 15 (7.7) 0.94 39 (28.3) 61 (31.4) 0.53 39 (28.3) 62 (32.0) 0.47
Treated for HT, n (%) 10 (7.2) 13 (6.7) 0.85 18 (13.0) 28 (14.4) 0.72 37 (26.8) 48 (24.7) 0.67
Controlled HT, n (%) 7 (5.1) 3 (1.5) 0.10 37 (26.8) 75 (38.7) 0.02 38 (27.5) 57 (29.4) 0.71
HT severity
HT stage 1b, n (%) 67 (48.6) 109 (56.2) 0.17 46 (33.3) 49 (25.3) 0.11 36 (26.1) 58 (29.9) 0.45
HT stage 2c, n (%) 64 (46.4) 82 (42.3) 0.46 55 (39.9) 70 (36.1) 0.48 64 (46.4) 79 (40.7) 0.31
HT controlled, n (%) 7 (5.1) 3 (1.5) 0.10 37 (26.8) 75 (38.7) 0.02 38 (27.5) 57 (29.4) 0.71
DM, n (%) 9 (6.5) 5 (2.6) 0.10 9 (6.5) 3 (1.5) 0.03 14 (10.1) 10 (5.2) 0.08
Smoke, n (%) 5 (3.6) 12 (6.2) 0.33 4 (2.9) 12 (6.2) 0.20 3 (2.2) 6 (3.1) 0.74
Alcohol, n (%) 11 (8.0) 8 (4.1) 0.14 16 (11.6) 8 (4.1) 0.01 19 (13.8) 7 (3.6) 0.001
Educational level
household head, n (%)
No formal education 67 (48.6) 139 (71.6) b0.001 67 (48.6) 139 (71.6) b0.001 67 (48.6) 139 (71.6) b0.001
Primary 31 (22.5) 34 (17.5) 31 (22.5) 34 (17.5) 31 (22.5) 34 (17.5)
Secondary 16 (11.6) 8 (4.1) 16 (11.6) 8 (4.1) 16 (11.6) 8 (4.1)
Tertiary 24 (17.4) 13 (6.7) 24 (17.4) 13 (6.7) 24 (17.4) 13 (6.7)
Consumption per capita
in US$,d median (IQR)
819.6 (583–1190) 655.8 (426–1079) 0.001 773.7 (519–1096) 620.3 (412–887) 0.001 801.1 (529–1126) 613.2 (406–973) b0.001
Insured, n (%) 1 (0.7) 0 (0.0) 0.42 0 (0.0) 81 (41.8) b0.001 0 (0.0) 81 (41.8) b0.001
Visited formal healthcare
provider in last
12 months, n (%)
55 (39.9) 57 (29.4) 0.05 55 (39.9) 103 (53.1) 0.02 66 (47.8) 100 (51.5) 0.51
Annual healthcare
expenditures in US$e,
median (IQR)
6.0 (2.5–14.5) 6.1 (2.0–15.0) 0.49 5.1 (1.6–5.7) 2.5 (1.0–7.9) 0.001 8.5 (2.9–17.6) 4.2 (1.6–14.0) 0.002
Abbreviations: BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HT: hypertension, IQR: interquartile range, DM: diabetes mellitus.
a Indicates difference control− program area (categorical variables: χ2 test/Fisher exact test, continuous variables: Kruskal–Wallis, ordinal variables: NP trend test).
b Deﬁned as systolic blood pressure between 140 and 159 mm Hg and/or diastolic blood pressure between 90 and 99 mm Hg.
c Deﬁned as systolic blood pressure of at least 160 mm Hg and/or diastolic blood pressure of at least 100 mm Hg.
d Indicates household expenditures on food and nonfood items (socioeconomic measure of wealth), corrected for inﬂation.
e Excludes premium, corrected for inﬂation.
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3.4.1. Effect on blood pressure
Mean SBP decreased by 9.30 mm Hg from baseline to midline and
by 5.11 mm Hg from baseline to endline in the PA compared to
5.67 mm Hg and 2.25 mm Hg respectively in the CA. Mean DBP
decreased by 4.67 mm Hg from baseline to midline and 3.82 mm Hg
from baseline to endline in the PA, compared to 2.99 mm Hg and 3.12
respectively in the CA (Fig. 2). After adjusting for confounders, the de-
crease in SBP that could be attributed to the program was 5.5 mm Hg
(95% CI, 0.60 to 10.41 mm Hg; P = 0.03) at midline and 4.97 mm Hg
(95% CI, −0.76 to +10.71 mm Hg; P = 0.09) at endline for SBP and
2.88 mm Hg (95% CI, 0.46 to 5.30 mm Hg; P = 0.02) at midline and
1.81 mm Hg (95% CI, −1.06 to +4.68 mm Hg; P = 0.21) at endline
for DBP (Table 2). The sensitivity analysis to estimate the effect of attri-
tion yielded very consistent results with an estimated effect of the pro-
gram of 5.54 mm Hg (95% CI,−0.32 to +11.40 mm Hg; P= 0.06) SBP
and 1.94 mm Hg (95% CI, −0.95 to +4.83 mm Hg, P = 0.19) DBP in
2013 (eTable1).
The program effect on BP at midline was mainly driven by respon-
dents with stage 1 hypertension at baseline who showed a 6.03 mm
Hg (95% CI, 0.14 to 11.92 mm Hg; P = 0.05) greater decrease in SBP
and a 3.64 mm Hg (95% CI, 0.11 to 7.17 mm Hg; P = 0.04) greater
decrease in DBP compared to the CA. The program effect at endline
was mainly driven by respondents with stage 2 hypertension at base-
line who showed an 11.43 mm Hg (95% CI, 1.62 to 21.23 mm Hg; P=
0.02) greater decrease in SBP and a 3.15 mm Hg (95% CI, −1.22 to
+7.53 mm Hg; P= 0.16) greater decrease in DBP compared to the CA
(Table 3, eFigures 2–3).3.4.2. Blood pressure control
The number of respondents with controlled BP increased from 3 re-
spondents (1.5%) at baseline to 57 respondents (29.4%) at endline in the
PA and from 7 respondents (5.1%) at baseline to 38 respondents (27.5%)
at endline in the CA (Table 1).When correcting for confounders the pro-
gram effect was estimated at an 11 percentage point (95% CI, 1 to 21;
P = 0.03) increase in BP control at midline and a 4 percentage point
(95% CI,−5 to 13; P= 0.38) increase at endline (Table 2).
3.4.3. Hypertension treatment coverage
Coverage of antihypertensive drug treatment increased from 13 re-
spondents (6.7%) at baseline to 48 respondents (24.7%) at endline in
the PA and from 10 respondents (7.2%) at baseline to 37 respondents
(26.8%) at endline in the CA (Table 1).When correcting for confounders
the program effect was estimated at a 9 percentage point (95% CI, 0
to 17; P = 0.046) increase in treatment coverage at midline and a 5
percentage point (95% CI, −5 to 14; P = 0.36) increase at endline
(Table 2).
3.4.4. Quality of hypertension care
At endline, 25.3%of the respondents in the PA and 21%of the respon-
dents in the CA (P = 0.37) reported healthcare use for hypertension.
Monitoring of hypertension was more intense in the PA with a mean
number of visits in the year prior to the endline survey of 8.5 (SD:
5.03) in the PA compared to 4.8 (SD: 4.06) in the CA (P = 0.002)
(eTable2). Respondents in the PA who visited a healthcare professional
had less out-of-pocket expenditures for hypertension care during
their last visit (2.10 USD [SD: 6.02] compared to 7.11 USD [SD: 5.74],
P= 0.001) (eTable2).
Fig. 2. Change in mean blood pressure over time in respondents with hypertension at
baseline. Note: The common trend assumption is the assumption that in absence of the
program, the program area would follow the trend observed in the control area, this is vi-
sualized in the ﬁgure above by the ‘common trend’ line. The difference between the com-
mon trend and the program area, represented by the arrows is the program effect. Sample
size for unadjusted and adjusted analysis was 996. All adjusted estimates corrected for:
being household head, marital status, work in past year, household size, yearly per capita
consumption excluding healthcare expenditures — corrected for inﬂation, wealth indica-
tor based on asset score 2009, diabetes, smoking and BMI-class. Interactions of time (fol-
low-up survey year) with education, age and baseline SBP and DBP respectively were
included in all adjusted estimates. All estimates were corrected for clustering at enumer-
ation area level and lower levels such as household and individual level.
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endline, for whom the source of medication was known, obtained their
antihypertensive medication from a formal healthcare provider com-
pared to 16 out of 37 respondents (43.2%) in the CA (P b 0.001)Table 2
Effect of the insurance program on respondents with hypertension at baseline.
Difference-in-differencesa
Unadjusted analyses
Coefﬁcient 95% CI
Systolic blood pressure (SBP)
Difference in change 2011 from baseline between areas −3.63 (−7.94
Difference in change 2013 from baseline between areas −2.86 (−8.21
Diastolic blood pressure (DBP)
Difference in change 2011 from baseline between areas −1.68 (−4.09
Difference in change 2013 from baseline between areas −0.70 (−3.68
Controlled hypertension (HT)
Difference in change 2011 from baseline between areas 0.15 (.06 to
Difference in change 2013 from baseline between areas 0.05 (− .05 t
Drug treatment for hypertension (HT)
Difference in change 2011 from baseline between areas 0.02 (− .07 t
Difference in change 2013 from baseline between areas −0.02 (− .11 t
The coefﬁcient for the variable “Difference in change from baseline between areas”measures t
reﬂects the true effect of the program in 2011 and 2013 respectively.
a Number of observations for unadjusted and adjusted analysis was 996 (332 patients with
status, work in past year, household size, yearly per capita consumption excluding healthcare ex
smoking and BMI-class. The following interactionswere included in all adjusted estimates: for S
baseline SBP andDBP respectively. For controlled HT: interaction of time (follow-up survey year
survey year) with education, religion, age, sex and baseline HT severity. All estimates were co
individual level.(eTable2). Respondents using medication obtained from a formal
healthcare provider showed a 10.96 mm Hg (95% CI, 1.31 to 20.61 mm
Hg; P= 0.03) greater decrease in SBP and a 7.03 mm Hg (95% CI, 3.07
to 11.00 mm Hg; P= 0.001) greater decrease in DBP from baseline to
endline compared to respondents who were not using medication
(both areas combined). Respondents who obtained medication from
an informal provider, showed similar non-signiﬁcant decrease in BP
compared to respondents who were not using antihypertensive medi-
cation (decrease of 3.72 mm Hg SBP; 95% CI, −10.78 to +18.23 mm
Hg; P = 0.61 and 1.75 mm Hg DBP; 95% CI,−6.07 to +9.57 mm Hg;
P = 0.66) (eTable3). Respondents who were on treatment in the PA
weremore likely to be highly adherent to their treatment (86.1%), com-
pared to respondents in the CA (50%, P= 0.003) (eTable2).
4. Discussion
Access to improved quality healthcare through health insurancewas
associated with a signiﬁcant longer-term reduction in BP in subjects
with moderate to severe (stage 2) hypertension, who are at highest
risk of CVD [12,13]. The observed difference in SBP reduction between
the PA and CA of 11.43 mm Hg, four years after start of the program,
translates into a more than 38% reduction in the risk of stroke and a
more than 26% reduction in the risk of ischemic heart disease [3].
Improved access to higher quality care in the PA has likely contributed
to the greater BP reduction. Respondents on treatment in the PA were
twice as likely to obtain their medication from a formal healthcare pro-
vider compared to respondents on treatment in the CA. Almost 60% of
respondents in the CA purchased (often cheaper) medication from in-
formal providers. This medication did not add any beneﬁt over not
using anymedication in reducing BP, suggesting poor quality treatment.
In addition, respondents in the PA were more intensely monitored, re-
ported better adherence to treatment, and incurred lower out-of-
pocket expenditures for hypertension care compared to the CA.
Mean BP in the overall hypertensive population (stage 1 and 2) de-
creased in both the PA and the CA between baseline and midline. This
is most likely the result of the increased awareness of hypertension
after our baseline survey, which resulted in increased treatment cover-
age in both the PA and the CA. However, a twofold greater reduction in
mean BP was observed in the PA compared to the CA, probably due toAdjusted analyses
P- value Coefﬁcient 95% CI P-value
to .68) 0.098 −5.50 (−10.41 to−.60) 0.028
to 2.49) 0.291 −4.97 (−10.71 to .76) 0.088
to .72) 0.168 −2.88 (−5.30 to− .46) 0.020
to 2.29) 0.644 −1.81 (−4.68 to 1.06) 0.213
.25) 0.002 0.11 (.01 to .21) 0.029
o .16) 0.310 0.04 (− .05 to .13) 0.377
o .11) 0.658 0.09 (.001 to .17) 0.046
o .08) 0.760 0.05 (− .05 to .14) 0.360
he difference in change from baseline between the program area and the control area and
each 3 observations). All adjusted estimates corrected for: being household head, marital
penditures— corrected for inﬂation, wealth indicator based on asset score 2009, diabetes,
BP and DBP outcomes: interaction of time (follow-up survey year)with education, age and
)with education andbaseline HT severity. For treatment HT: interaction of time (follow-up
rrected for clustering at enumeration area level and lower levels such as household and
Table 3
Effect of the insurance program on respondents with hypertension at baseline; stratiﬁed by baseline hypertension severity.
Difference-in-differencesa
Unadjusted analyses Adjusted analyses
Coefﬁcient 95% CI P- value Coefﬁcient 95% CI P- value
Baseline stage 1b hypertension (HT)
Systolic blood pressure (SBP)
Difference in change 2011 from baseline between areas -4.97 (−10.49 to .55) 0.077 −6.03 (−11.92 to−.14) 0.045
Difference in change 2013 from baseline between areas −1.47 (−7.78 to 4.84) 0.643 −1.64 (−7.93 to 4.65) 0.605
Diastolic blood pressure (DBP)
Difference in change 2011 from baseline between areas −2.38 (−5.81 to 1.06) 0.172 −3.64 (−7.17 to−.11) 0.043
Difference in change 2013 from baseline between areas −1.63 (−5.44 to 2.18) 0.397 −2.01 (−5.70 to 1.68) 0.282
Baseline stage 2c hypertension (HT)
Systolic blood pressure (SBP)
Difference in change 2011 from baseline between areas −1.96 (−9.01 to 5.08) 0.580 −5.54 (−14.43 to 3.34) 0.218
Difference in change 2013 from baseline between areas −5.67 (−14.86 to 3.51) 0.222 −11.43 (−21.23 to−1.62) 0.023
Diastolic blood pressure (DBP)
Difference in change 2011 from baseline between areas −1.19 (−5.43 to 3.04) 0.576 −2.50 (−6.24 to 1.25) 0.188
Difference in change 2013 from baseline between areas − .28 (−4.64 to 4.07) 0.897 −3.15 (−7.53 to 1.22) 0.155
The coefﬁcient for the variable “Difference in change from baseline between areas”measures the difference in change from baseline between the program area and the control area and
reﬂects the true effect of the program in 2011 and 2013 respectively.
a The number of observations for the unadjusted and adjusted analysis was 528 for hypertension stage 1 and 438 for hypertension stage 2 (3 observations for each individual with
measured hypertension at baseline). 30 observations (10 individuals with a normal blood pressure at baseline who were classiﬁed as hypertensive because they were using antihyper-
tensive treatment) were excluded from this analysis. All adjusted estimates corrected for: being household head, marital status, work in past year, household size, yearly per capita con-
sumption excluding healthcare expenditures — corrected for inﬂation, wealth indicator based on asset score 2009, diabetes, smoking and BMI-class. The following interactions were
included in all adjusted estimates: interaction of time (follow-up survey year) with education, age and baseline SBP and DBP respectively. All estimates were corrected for clustering at
enumeration area level and lower levels such as household and individual level.
b HT stage 1 is deﬁned as systolic blood pressure between 140 and 159 mm Hg and/or diastolic blood pressure between 90 and 99 mm Hg.
c HT stage 2 is deﬁned as systolic blood pressure of at least 160 mm Hg and/or diastolic blood pressure of at least 100 mm Hg.
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term access and adherence to uninterrupted quality treatment [14].
Even in high income countries where access to care is guaranteed, it is
difﬁcult to motivate patients to adhere to antihypertensive medication
and treatment monitoring for longer periods of time [15,16]. This may
explain the increase in BP in both areas observed between midline
and endline in respondents with mild (stage 1) hypertension. In addi-
tion, in any ageing cohort, BP increases over time [17]. However, in
the PA, SBP reduction was sustained in the longer-term in respondents
withmore severe hypertension, whomay bemoremotivated to contin-
ue treatment. This ﬁnding highlights the potential of health insurance
programs, which include improvement of quality of care, to achieve
sustained CVD risk factor control in vulnerable populations in LMICs.
A limitednumber of studies fromLMICs evaluated the effect of insur-
ance on health outcomes, and have provided conﬂicting results [18–27].
A lack of quality of care as well as possible methodological limitations
such as small sample sizes, inadequate control for potential reverse cau-
sality, and other confounding factors, and the use of health outcome
measures that are not suitable to capture changes in health status,
have been mentioned as a potential reason for a lack of effect in some
studies [19–21,25]. Most studies compared insured with non-insured
individuals and selection bias in those insured is likely to occur. In addi-
tion, very few studies evaluated longer-term effects [24,26,27], which is
essential to determine whether health insurance can be effective for
treatment of chronic conditions. Our study demonstrates that access
to high quality care through health insurance resulted in sustained
health effects. The strength of our study is the longer-term prospective
follow up, and the conservative intention-to-treat analysis approach to
eliminate selection bias. In our study, 58% of the individuals in the PA
were not enrolled in the insurance program at the time of the surveys,
thereby diluting the effect of insurance. However, this reﬂects a real
world situation in which not all individuals choose to enroll and in-
creases the generalizability of our results to other rural settings in SSA.
It is remarkable that we were able to demonstrate longer-term health
beneﬁts using such a conservative analysis approach [7].
A limitation of our study was the non-randomized rollout of the in-
surance program. We used a second best approach by including a con-
trol group and by analyzing the data using difference-in-differencesanalysis. Socioeconomic status at baseline was higher and respondents
were younger in the CA compared to the PA. Respondents unaware of
their hypertension at baseline who are more educated and wealthier
are probably more likely to seek care after BP screening. In addition,
BP reduction is more difﬁcult to achieve in older patients [28,29].
These baseline differences between groups are likely to reduce the
estimated effect of the insuranceprogramand explain the difference be-
tween the observed effects of the insurance program in the unadjusted
and adjusted analyses. Longitudinal data were not available for 41.6% of
the study population. Given the setting of our study in rural SSA, where
migration is common and people are difﬁcult to track, the observed
attrition rate after four years is relatively low. In addition, the results
of the sensitivity analyses indicated that our results were robust and
that attrition did not affect our ﬁndings.5. Conclusions
Increased access to and improved quality of healthcare through an
insurance programwas associatedwith a signiﬁcant longer-term reduc-
tion in BP in subjects with moderate to severe hypertension, who are at
highest risk of CVD. Scale-up of health insurance programs that cover
costs of care and improve the quality of care is needed to combat the
increasing burden of CVD in SSA.Author contributions
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